Acciones Iqvia Holdings Inc Nyse
Acciones
US74876Y1010
Biotecnología e investigación médica
Ventas 2024 * | 15,53 mil M 14,49 mil M | Ventas 2025 * | 16,68 mil M 15,56 mil M | Capitalización | 42,4 mil M 39,56 mil M |
---|---|---|---|---|---|
Resultado Neto 2024 * | 1321 M 1232,43 M | Resultado Neto 2025 * | 1584 M 1477,79 M | VE / Ventas 2024 * | 3,51 x |
Deuda neta 2024 * | 12,06 mil M 11,25 mil M | Deuda neta 2025 * | 11,62 mil M 10,84 mil M | VE / Ventas 2025 * | 3,24 x |
P/E ratio 2024 * |
31,9
x | P/E ratio 2025 * |
26,7
x | Empleados | - |
Rendimiento 2024 * |
-
| Rendimiento 2025 * |
-
| Flotante | 69,76 % |
Último transcript sobre Iqvia Holdings Inc
Directores | Puesto | Edad | Desde |
---|---|---|---|
Ari Bousbib
CEO | Chief Executive Officer | 63 | 03/10/16 |
Ronald Bruehlman
DFI | Director of Finance/CFO | 63 | 01/08/20 |
James Berkshire
COO | Chief Operating Officer | 51 | 01/07/17 |
Administradores | Puesto | Edad | Desde |
---|---|---|---|
John Danhakl
BRD | Director/Board Member | 67 | 03/10/16 |
Colleen Goggins
BRD | Director/Board Member | 68 | 27/07/17 |
Ari Bousbib
CEO | Chief Executive Officer | 63 | 03/10/16 |
Varia. 1 de ene. | Capi. | |
---|---|---|
+44,30 % | 40,04 mil M | |
-6,20 % | 28,31 mil M | |
+6,55 % | 24,94 mil M | |
-21,66 % | 18,96 mil M | |
+29,96 % | 12,3 mil M | |
-1,57 % | 11,95 mil M | |
+16,03 % | 11,32 mil M | |
-4,80 % | 11,55 mil M | |
-4,38 % | 9497,27 M |